@FiercePharma: Reports of serious reactions to Affymax's Omontys surfaced last August, WSJ says, 6 months b/f recall. More | Follow @FiercePharma
@EricPFierce: Pfizer's Xeljanzi forecast to hit $1.86 billion by 2016 but Amarin's Vascepa disappoints. Story | Follow @EricPFierce
> Lonza and Teva Pharmaceutical Industries ($TEVA), which suspended their work in October on a biosimilar of Roche's ($RHHBY) drug MabThera, are evaluating whether to proceed with their biosimilar joint venture. Story
> Pfizer ($PFE) was unable to derail a shareholder lawsuit that claims execs made misleading statements about the safety of sales potential of arthritis drugs Celebrex and Bextra. Story
> Teva has gotten FDA approval for Quartette, a new birth control drug developed to minimize breakthrough bleeding between periods. Item
> Canada's Apotex, already in a NAFTA fight with U.S. over a 2009 FDA import ban, has found itself back in the agency's doghouse. Story
> Ranbaxy Laboratories has restored supplies of generic Lipitor in the U.S. Report
@FierceMedDev: Dx approach offers chance to spot pancreatic cancer earlier. Story | Follow @FierceMedDev
@MarkHFierce: Sony and Olympus have delayed their joint medical device venture again. Talk about unrealized potential. More | Follow @MarkHFierce
@DamianFierce: A Chinese court is asking the SFDA to crack down on local clinical trial regulations. Article | Follow @DamianFierce
> ResMed battles Taiwanese outfit in apnea device patent fight. Item
> Olympus, Sony postpone joint medical device venture indefinitely. Article
> Covidien defeats J&J/Ethicon in surgical tool patent battle. News
Biotech News
@FierceBiotech: Sanofi to build $75m plant in Vietnam. Market there growing fast, and so is payer coverage. Article | Follow @FierceBiotech
@JohnCFierce: While India's SC strikes at pharma, the U.K. tees up a sweet tax deal for patented pharma products--the "patent box." More | Follow @JohnCFierce
@RyanMFierce: Amgen claimed Big Data software prize in $415M deCODE buyout. Report | Follow @RyanMFierce
> New math on biosimilars sends a chilling message to Lonza/Teva team. More
> Clashing stands of India, U.K. on drug patents, R&D will offer clear lessons. Article
> J&J wins first FDA approval for new class of diabetes drug. News
CRO News
> Biotrial takes tech, talent from failing Forenap. Story
> ReSearch launches joint venture with Japanese CRO. News
> bioRASI buys Ukraine CRO for E. Europe heft. Article
> Frontage gets FDA chiding over Chinese lab. Item
> Chinese court wants tougher clinical trial regs. Report
Biotech IT News
> George Church-affiliated startup blueprints genetic data marketplace. News
> FoldIt creator wins Bill Gates nod for science crowdfunding site. Item
> Sequoia-backed genomics startup, others face who-pays hurdle. Story
> NSF touts role of supercomputer in autism, neuroscience discoveries. Article
> Big Data sheds light on pharma's 'Small Data' problems. Industry Voices
> 5 keys to going mobile in pharma. Editor's Corner
And Finally... India, which has significantly increased the number of drugs covered by price controls, says manufacturers must give a 6-month notice if they are discontinuing a product and that the government can force them to continue production to meet essential needs. Report